MDNA
Medicenna Therapeutics Corp.
Set alert
0.16 0.00 0.00%
0.15125 Day range 0.1999
52-week range unavailable
- Open
- 0.1993
- Prev close
- 0.157
- Mkt cap
- 0
- Vol
- 1.26M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.15125
- High
- 0.1999
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2023
- 50-d avg
- 0.00
- 200-d avg
- 0.00
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Nov 3, 2023
Expected Nov 3, 2023. Consensus EPS estimate 0.00.
Financials — quick view
MDNA Revenue — quarterly 0
MDNA Net income — quarterly -2.86M
MDNA EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2023 | Sep 1, 2023 | -0.05 | — | — | — |
| Jul 28, 2023 | Jun 1, 2023 | -0.04 | — | — | — |
| Jun 27, 2023 | Mar 1, 2023 | -0.06 | — | — | — |
| Feb 7, 2023 | Dec 1, 2022 | -0.06 | — | — | — |
| Nov 4, 2022 | Sep 1, 2022 | -0.06 | — | — | — |
| Aug 15, 2022 | Jun 1, 2022 | -0.07 | — | — | — |
News
- Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
- Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
- Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
- Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
- Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
- Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
- Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
- Medicenna Announces the Launch of a Marketed Public Offering of Securities
- Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
- Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
Your note
Sign in to keep a note on MDNA — it syncs with the Stock Master app.